Epigenetics in cancer: implications for early detection and prevention

被引:106
作者
Verma, M [1 ]
Srivastava, S [1 ]
机构
[1] NCI, Canc Biomarkers Res Grp, Div Canc Prevent, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S1470-2045(02)00932-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Knowledge of the molecular events that occur during the early stages of cancer has advanced rapidly. The initiation and development of cancer involves several molecular changes, which include epigenetic alterations. Epigenetics is the study of modifications in gene expression that do not involve changes in DNA nucleotide sequences. Modifications in gene expression through methylation of DNA and remodelling of chromatin via histone proteins are believed to be the most important of the epigenetic changes. The study of epigenetics offers great potential for the identification of biomarkers that can be used to detect and diagnose cancer in its earliest stages and to accurately assess individual risk. There has been a recent surge of interest among researchers as variations in the methylation of DNA have been shown to be the most consistent molecular changes in many neoplasms. An important distinction between a genetic and an epigenetic change in cancer is that epigenetic changes can be reversed more easily by use of therapeutic interventions. The discovery of these basic premises should stimulate much future research on epigenetics.
引用
收藏
页码:755 / 763
页数:9
相关论文
共 74 条
[61]   Imprinting and the initiation of gene silencing in the germ line [J].
Surani, MA .
CELL, 1998, 93 (03) :309-312
[62]   Genetics - Immaculate misconception [J].
Surani, MA .
NATURE, 2002, 416 (6880) :491-493
[63]   Epigenetics of latent Epstein-Barr virus genomes:: High resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes [J].
Takacs, M ;
Salamon, D ;
Myöhänen, S ;
Li, H ;
Segesdi, J ;
Ujvari, D ;
Uhlig, J ;
Niller, HH ;
Wolf, H ;
Berencsi, G ;
Minarovits, J .
BIOLOGICAL CHEMISTRY, 2001, 382 (04) :699-705
[64]   Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease - Application of PCR-based analysis [J].
Tao, Q ;
Swinnen, LJ ;
Yang, J ;
Srivastava, G ;
Robertson, KD ;
Ambinder, RF .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :619-625
[65]   Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation [J].
Tierney, RJ ;
Kirby, HE ;
Nagra, JK ;
Desmond, J ;
Bell, AI ;
Rickinson, AB .
JOURNAL OF VIROLOGY, 2000, 74 (22) :10468-10479
[66]   Epigenetic gene silencing in cancer [J].
Tycko, B .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (04) :401-407
[67]  
VACHTENHEIM J, 1994, CANCER RES, V54, P1145
[68]   Meeting highlights: National Cancer Institute Workshop on Molecular Signatures of Infectious Agents [J].
Verma, M ;
Lambert, PF ;
Srivastava, SK .
DISEASE MARKERS, 2001, 17 (03) :191-201
[69]  
Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291
[70]   Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation [J].
Wade, PA ;
Gegonne, A ;
Jones, PL ;
Ballestar, E ;
Aubry, F ;
Wolffe, AP .
NATURE GENETICS, 1999, 23 (01) :62-66